Browsing tag:

epilepsy


While Brivaracetam is being evaluated as an adjunctive therapy in patients diagnosed with Epilepsy and partial onset seizures, animal models have piqued the curiosity of R&D experts as to Brivaracetam being a potential treatment for Alzheimer’s patients. As a unique product with a high-affinity synaptic vesicle protein 2A ligand, Brivaracetam is currently marketed by UCB,[…]

Read More

On March 11, 2014 the FDA approved Topiramate, marketed as Qudexy™ XR by Upsher-Smith Laboratories, for the treatment of partial-onset seizures (POS) or primary generalized tonic-clonic seizures in patients 10+ years of age. It is also approved as adjunctive therapy in patients 2+ years of age for the aforementioned seizures, and seizures associated with Lennox-Gastaut[…]

Read More

Gabapentin, also known as Neurontin, has long been a stable and effective treatment for patients who experience seizures, certain forms of epilepsy and pain from shingles. New research has indicated another effectual use for Gabapentin, CAS 60142-96-3, as a treatment to help combat symptoms of severe morning sickness. Known as hyperemesis gravidarum, this extreme form[…]

Read More

Topiramate CAS# 97240-79-4, is also known as the brand name medication Topamax. Marketed by Janssen, Topamax has a patent expiration of October 13, 2015. As an effectual and reliable medication to treat patients with both epilepsy and migraines, topiramate is known for it’s effectiveness as monotherapy or adjunctive therapy for the treatment of epilepsy. Tablets[…]

Read More

Lacosamide, CAS# 175481-36-4, is marketed under the trade name Vimpat. Previously known as erlosamide, lacosamide is a medication for both partial onset seizures. Often used in conjunction with other anti-eplileptic drugs, lacosamide is an anticonvulsant. LGM Pharma is not only a supplier of lacosamide, but they also offer support for clients throughout the research and[…]

Read More